SRPT logo

Sarepta Therapeutics (SRPT) Accounts receivable

Annual accounts receivable:

$601.99M+$201.66M(+50.37%)
December 31, 2024

Summary

  • As of today (May 29, 2025), SRPT annual accounts receivable is $601.99 million, with the most recent change of +$201.66 million (+50.37%) on December 31, 2024.
  • During the last 3 years, SRPT annual accounts receivable has risen by +$449.00 million (+293.48%).
  • SRPT annual accounts receivable is now at all-time high.

Performance

SRPT Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTbalance sheet metrics

Quarterly accounts receivable:

$659.37M+$57.38M(+9.53%)
March 1, 2025

Summary

  • As of today (May 29, 2025), SRPT quarterly accounts receivable is $659.37 million, with the most recent change of +$57.38 million (+9.53%) on March 1, 2025.
  • Over the past year, SRPT quarterly accounts receivable has increased by +$280.56 million (+74.07%).
  • SRPT quarterly accounts receivable is now at all-time high.

Performance

SRPT Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTbalance sheet metrics

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

SRPT Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+50.4%+74.1%
3 y3 years+293.5%+270.0%
5 y5 years+565.9%+633.0%

SRPT Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+293.5%at high+270.0%
5 y5-yearat high+565.9%at high+633.0%
alltimeall timeat high>+9999.0%at high>+9999.0%

SRPT Accounts receivable History

DateAnnualQuarterly
Mar 2025
-
$659.37M(+9.5%)
Dec 2024
$601.99M(+50.4%)
$601.99M(+38.5%)
Sep 2024
-
$434.52M(+20.7%)
Jun 2024
-
$360.00M(-5.0%)
Mar 2024
-
$378.81M(-5.4%)
Dec 2023
$400.33M(+86.5%)
$400.33M(+25.6%)
Sep 2023
-
$318.86M(+34.6%)
Jun 2023
-
$236.81M(+5.8%)
Mar 2023
-
$223.84M(+4.3%)
Dec 2022
$214.63M(+40.3%)
$214.63M(+6.5%)
Sep 2022
-
$201.51M(-1.2%)
Jun 2022
-
$203.85M(+14.4%)
Mar 2022
-
$178.19M(+16.5%)
Dec 2021
$152.99M(+51.7%)
$152.99M(+2.5%)
Sep 2021
-
$149.32M(+17.5%)
Jun 2021
-
$127.05M(+7.9%)
Mar 2021
-
$117.73M(+16.7%)
Dec 2020
$100.87M(+11.6%)
$100.87M(-3.5%)
Sep 2020
-
$104.49M(+10.3%)
Jun 2020
-
$94.69M(+5.3%)
Mar 2020
-
$89.96M(-0.5%)
Dec 2019
$90.41M(+87.4%)
$90.41M(+34.4%)
Sep 2019
-
$67.26M(+19.7%)
Jun 2019
-
$56.19M(+13.0%)
Mar 2019
-
$49.72M(+3.0%)
Dec 2018
$48.25M(+69.1%)
$48.25M(+0.9%)
Sep 2018
-
$47.81M(+13.7%)
Jun 2018
-
$42.06M(+8.1%)
Mar 2018
-
$38.92M(+36.4%)
Dec 2017
$28.54M(+445.9%)
$28.54M(+15.3%)
Sep 2017
-
$24.75M(+39.1%)
Jun 2017
-
$17.79M(+44.9%)
Mar 2017
-
$12.28M(+134.9%)
Dec 2016
$5.23M(+31.5%)
$5.23M(+31.2%)
Sep 2016
-
$3.99M(+0.1%)
Jun 2016
-
$3.98M(-0.2%)
Mar 2016
-
$3.99M(+0.3%)
Dec 2015
$3.98M
$3.98M(+45.5%)
Sep 2015
-
$2.73M(+13.1%)
DateAnnualQuarterly
Jun 2015
-
$2.42M(0.0%)
Mar 2015
-
$2.42M(0.0%)
Dec 2014
$2.42M(-31.6%)
$2.42M(-28.1%)
Sep 2014
-
$3.36M(-35.7%)
Jun 2014
-
$5.23M(-33.4%)
Mar 2014
-
$7.85M(+122.4%)
Dec 2013
$3.53M(-25.1%)
$3.53M(-47.5%)
Sep 2013
-
$6.72M(+77.4%)
Jun 2013
-
$3.79M(-33.0%)
Mar 2013
-
$5.65M(+19.9%)
Dec 2012
$4.71M(+29.7%)
$4.71M(+90.5%)
Sep 2012
-
$2.47M(-65.5%)
Jun 2012
-
$7.18M(+39.8%)
Mar 2012
-
$5.13M(+41.3%)
Dec 2011
$3.63M(+12.7%)
$3.63M(-14.9%)
Sep 2011
-
$4.27M(-60.8%)
Jun 2011
-
$10.89M(-19.8%)
Mar 2011
-
$13.58M(+321.1%)
Dec 2010
$3.22M(+54.6%)
$3.22M(-38.5%)
Sep 2010
-
$5.24M(+143.4%)
Jun 2010
-
$2.15M(+30.6%)
Mar 2010
-
$1.65M(-21.0%)
Dec 2009
$2.08M(-58.1%)
$2.08M(-63.2%)
Sep 2009
-
$5.67M(+68.8%)
Jun 2009
-
$3.36M(+7.5%)
Mar 2009
-
$3.13M(-37.1%)
Dec 2008
$4.97M(+73.2%)
$4.97M(+21.9%)
Sep 2008
-
$4.08M(+52.9%)
Jun 2008
-
$2.67M(-34.2%)
Mar 2008
-
$4.05M(+41.2%)
Dec 2007
$2.87M(+5472.4%)
$2.87M(+63.9%)
Sep 2007
-
$1.75M(+56.4%)
Jun 2007
-
$1.12M(+102.9%)
Mar 2007
-
$551.80K(+971.5%)
Dec 2006
$51.50K(-95.8%)
$51.50K(-16.0%)
Sep 2006
-
$61.30K(+38.1%)
Jun 2006
-
$44.40K(-94.7%)
Mar 2006
-
$840.20K(-32.0%)
Dec 2005
$1.24M
$1.24M

FAQ

  • What is Sarepta Therapeutics annual accounts receivable?
  • What is the all time high annual accounts receivable for Sarepta Therapeutics?
  • What is Sarepta Therapeutics annual accounts receivable year-on-year change?
  • What is Sarepta Therapeutics quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Sarepta Therapeutics?
  • What is Sarepta Therapeutics quarterly accounts receivable year-on-year change?

What is Sarepta Therapeutics annual accounts receivable?

The current annual accounts receivable of SRPT is $601.99M

What is the all time high annual accounts receivable for Sarepta Therapeutics?

Sarepta Therapeutics all-time high annual accounts receivable is $601.99M

What is Sarepta Therapeutics annual accounts receivable year-on-year change?

Over the past year, SRPT annual accounts receivable has changed by +$201.66M (+50.37%)

What is Sarepta Therapeutics quarterly accounts receivable?

The current quarterly accounts receivable of SRPT is $659.37M

What is the all time high quarterly accounts receivable for Sarepta Therapeutics?

Sarepta Therapeutics all-time high quarterly accounts receivable is $659.37M

What is Sarepta Therapeutics quarterly accounts receivable year-on-year change?

Over the past year, SRPT quarterly accounts receivable has changed by +$280.56M (+74.07%)
On this page